We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > carfilzomib

News List

Four-drug combo therapy shows benefit for newly-diagnosed myeloma patients pharmatimes
July 27, 2021
A four-drug combination therapy has shown significant benefit for patients with newly diagnosed myeloma, according to a new analysis led by researchers from The Institute of Cancer Research, London (ICR).
Natco gets US FDA approval for Carfilzomib vials expresspharma
June 16, 2021
The parties have received final approval for 10 mg and 60 mg strengths of the product and tentative approval for 30 mg strength of the product.
EC approves new Sarclisa indication pharmatimes
April 20, 2021
The European Commission has approved Sanofi’s Sarclisa in combination with standard of care regimen carfilzomib and dexamethasone (Kd) for the treatment of relapsed multiple myeloma.
US expand use of Janssen's Darzalex pharmatimes
August 21, 2020
US regulators have approved Janssen's Darzalex (daratumumab) in combination with carfilzomib and dexamethasone (DKd) for the treatment of adults with relapsed/refractory multiple myeloma who have received one to three previous lines of therapy.